Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT00078806
Etanercept (Enbrel®) in Psoriasis - Pediatrics
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 211
- Registration Number
- NCT00078819
Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00078793
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase 2
- Conditions
- Lymphoma
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005959
- Locations
- 🇺🇸
Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States
🇺🇸Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States
🇺🇸Intermountain Hematology/Oncology Associates, Inc., Salt Lake City, Utah, United States
Pegfilgrastim PBPC Mobilization Study
Phase 2
Completed
- Conditions
- LymphomaNon-Hodgkin's LymphomaHodgkin's LymphomaHematologyOncology
- Interventions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT00066092
Heart Failure and Anemia
Phase 2
Completed
- Conditions
- Heart FailureAnemia
- First Posted Date
- 2002-11-19
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00049985
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00044902
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Phase 2
Completed
- Conditions
- Low Bone Mineral Density
- Interventions
- First Posted Date
- 2002-08-07
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 412
- Registration Number
- NCT00043186
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-08-06
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 380
- Registration Number
- NCT00042653
Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
Phase 2
Completed
- Conditions
- Secondary HyperparathyroidismChronic Renal Insufficiency
- Interventions
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT00042432
© Copyright 2025. All Rights Reserved by MedPath